Medicenna Therapeutics Corp - MDNA STOCK NEWS

Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNA), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.

Medicenna Therapeutics (MDNA) is a clinical-stage immunotherapy company at the forefront of developing novel and highly selective versions of IL-2, IL-4, and IL-13 superkines and first-in-class Empowered Cytokines (ECs). With a mission to lead in the development and commercialization of targeted ECs and superkines, Medicenna aims to revolutionize treatment for a broad range of cancers and immune-mediated diseases. The company leverages its expertise and collaborates with world-class researchers to create unique superkines.

Medicenna's innovative approach allows these superkines to function either as standalone short or long-acting therapeutics or to be fused with pro-apoptotic proteins. This fusion precisely delivers potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment, and cancer stem cells, sparing healthy cells from harm. Additionally, these superkines can be fused with antibodies to create novel 'immunocytokines' or combined with other treatment modalities.

Currently, Medicenna is engaged in various promising projects. A notable recent achievement includes the characterization of its tumor-targeting and activatable T-MASK platform, designed to enhance tumor accumulation and tolerability of potent immune modulators. This innovation was presented at a significant conference on November 3, 2023.

As Medicenna continues to advance its pipeline of targeted treatments, it remains committed to transforming the therapeutic landscape for cancer and immune-related conditions. The company's financial health is supported by strategic partnerships and a focus on groundbreaking research and development.

09/06/2023 07:00 AM

News

Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary

Medicenna CEO to participate in fireside chat at H.C. Wainwright Conference

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.74%

Tags

08/28/2023 07:00 AM

News

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

Rhea-AI Summary

Medicenna appoints Jeff Caravella as CFO, demonstrating commitment to expanding operations in Boston. Caravella brings 20+ years of financial leadership experience in the biotech industry. Medicenna initiates Phase 2 study with MDNA11 and seeks partnerships for bizaxofusp and Superkines.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

Tags

08/14/2023 07:00 AM

News

Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management

Rhea-AI Summary

Medicenna Therapeutics Corp. has appointed Brent Meadows as its Chief Business Officer (CBO) to establish a world-class C-suite in Boston. Meadows brings over 25 years of experience in business development and marketing at large pharma and biotech companies. The company is also strengthening its management team with new appointments and promotions in investor relations, external collaborations, finance, and oncology research. Additionally, Elizabeth Williams, the CFO, has chosen to pursue another biotech opportunity, and a search for her replacement is underway.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.26%

Tags

08/09/2023 07:30 AM

News

Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Rhea-AI Summary

Medicenna announces positive results in Phase 1/2 ABILITY Study for MDNA11

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.33%

Tags

08/08/2023 07:00 AM

News

Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Rhea-AI Summary

Medicenna appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.48%

Tags

08/04/2023 07:00 AM

News

Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023

Rhea-AI Summary

Medicenna to provide clinical update on MDNA11 in Phase 1/2 ABILITY study

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

13.21%

Tags

08/01/2023 09:30 AM

News

Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.13%

Tags

07/28/2023 07:00 AM

News

Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.27%

Tags

07/25/2023 07:00 AM

News

Medicenna Presents at National Brain Tumor Society's Research Round Table

Rhea-AI Summary

Medicenna's President and CEO, Dr. Fahar Merchant, presented at the Brain Cancer Research Roundtable organized by the National Brain Tumor Society to discuss the use of external control data in brain tumor clinical trials. The company's Phase 2b trial results for MDNA55 (bizaxofusp) were highlighted, showing more than doubled median survival in end-stage rGBM patients compared to a well-matched external control.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.09%

Tags

07/05/2023 07:00 AM

News

Medicenna Extends Period to Exercise Certain Warrants

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.05%

Tags

FAQ

What does Medicenna Therapeutics specialize in?

Medicenna Therapeutics specializes in developing novel and highly selective versions of IL-2, IL-4, and IL-13 superkines and first-in-class Empowered Cytokines (ECs) for treating cancer and immune-mediated diseases.

What are superkines?

Superkines are engineered cytokines with enhanced properties. They can be used as short or long-acting therapeutics or fused with other proteins to deliver targeted treatments to cancer cells and the tumor micro-environment.

How does Medicenna's T-MASK platform work?

The T-MASK platform is a tumor-targeting and activatable system designed to improve the accumulation and tolerability of potent immune modulators in tumors, sparing healthy tissues.

What are empowered cytokines (ECs)?

Empowered Cytokines (ECs) are enhanced versions of natural cytokines that have been genetically engineered to improve their therapeutic effects and target cancer cells more effectively.

What recent achievements has Medicenna made?

A recent achievement includes the presentation of their T-MASK platform, which enhances tumor accumulation and tolerability of immune modulators, at a major conference on November 3, 2023.

What is the company's mission?

Medicenna's mission is to lead in the development and commercialization of targeted ECs and superkines to treat a broad range of cancers and immune-mediated diseases.

How does Medicenna ensure the safety of its treatments?

Medicenna's treatments are designed to precisely target cancer cells and the tumor micro-environment without harming healthy cells, ensuring a safer therapeutic approach.

What are immunocytokines?

Immunocytokines are cytokines fused with antibodies, combining the properties of both to improve targeting and efficacy in cancer treatment.

How does Medicenna collaborate with other researchers?

Medicenna collaborates with world-class researchers to harness cutting-edge science and expertise, driving innovation in their therapeutic developments.

What is the financial outlook for Medicenna?

Medicenna's financial health is bolstered by strategic partnerships, ongoing research and development, and a pipeline of promising therapeutic candidates.